TLP Group LLC trimmed its position in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 44.8% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 580,000 shares of the biotechnology company’s stock after selling 470,000 shares during the quarter. Aimmune Therapeutics makes up approximately 12.7% of TLP Group LLC’s investment portfolio, making the stock its largest position. TLP Group LLC owned about 1.00% of Aimmune Therapeutics worth $18,461,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Republic Investment Management Inc. purchased a new stake in Aimmune Therapeutics in the 4th quarter valued at $202,000. Virtu Financial LLC purchased a new stake in Aimmune Therapeutics in the 4th quarter valued at $239,000. Teacher Retirement System of Texas purchased a new stake in Aimmune Therapeutics in the 4th quarter valued at $282,000. Wedbush Securities Inc. purchased a new stake in Aimmune Therapeutics in the 1st quarter valued at $292,000. Finally, MYDA Advisors LLC purchased a new stake in Aimmune Therapeutics in the 4th quarter valued at $378,000. Hedge funds and other institutional investors own 79.49% of the company’s stock.

In related news, insider Douglas T. Sheehy sold 3,296 shares of the stock in a transaction dated Tuesday, May 22nd. The stock was sold at an average price of $33.00, for a total transaction of $108,768.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Stephen George Dilly sold 61,197 shares of the stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $32.62, for a total value of $1,996,246.14. Following the transaction, the insider now directly owns 376,505 shares in the company, valued at approximately $12,281,593.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 364,493 shares of company stock worth $11,580,119. 14.70% of the stock is owned by corporate insiders.

Shares of NASDAQ AIMT traded down $0.03 during mid-day trading on Thursday, reaching $30.16. 2,032 shares of the company’s stock were exchanged, compared to its average volume of 784,865. The stock has a market cap of $1.80 billion, a PE ratio of -11.59 and a beta of -0.34. Aimmune Therapeutics Inc has a 52-week low of $16.25 and a 52-week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.21). During the same period last year, the firm posted ($0.52) earnings per share. analysts expect that Aimmune Therapeutics Inc will post -3.14 EPS for the current fiscal year.

Several brokerages have issued reports on AIMT. Cantor Fitzgerald restated a “buy” rating on shares of Aimmune Therapeutics in a report on Tuesday, February 20th. Wedbush reiterated an “outperform” rating and set a $72.00 price target on shares of Aimmune Therapeutics in a report on Tuesday, March 6th. Deutsche Bank set a $30.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 20th. Credit Suisse Group set a $45.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 20th. Finally, Roth Capital increased their price target on Aimmune Therapeutics from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, March 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $53.67.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.